Fu Qingguo, Zhang Wei, Meng Fandong, Guo Renxuan, Yao Zhenyu
The Second General Surgery Department, the First Affiliated Hospital of China Medical University, Shenyang 110001.
Chin Med Sci J. 2002 Sep;17(3):153-6.
To study the efficacy and explore the mechanism of the anti-tumor immunity elicited by heat shock protein 70-peptide complexes (HSP70-PC) derived from tumor cells.
Cells culture, flow cytometric analysis, affinity chromatography for protein purification, SDS-PAGE, Western-blotting and animal experiment were used.
HSP70-PC immunization rendered protective effect to both naive tumorl-bearing mice. All of the naive mice obtained complete resistance to Hcaf cell attack; 40% of the tumor-bearing mice survived for over 90 days, whereas the mice of control group died within 2 weeks (P < 0.01). CD8+ subset of T lymphocytes in the peripheral blood of immunized mice increased by 12%.
HSP70-PC induces anti-tumor immunity via activation of cytotoxic T lymphocytes (CTLs), and it possesses strong tumor vaccine effect. Our research adds more evidence to support the clinical use of HSP70-PC to fight human cancers.
研究肿瘤细胞来源的热休克蛋白70-肽复合物（HSP70-PC）引发的抗肿瘤免疫的疗效并探索其机制。
采用细胞培养、流式细胞术分析、蛋白质纯化的亲和层析、十二烷基硫酸钠-聚丙烯酰胺凝胶电泳、蛋白质免疫印迹法及动物实验。
HSP70-PC免疫对未患肿瘤的荷瘤小鼠均有保护作用。所有未患肿瘤的小鼠对Hcaf细胞攻击获得完全抗性；40%的荷瘤小鼠存活超过90天，而对照组小鼠在2周内死亡（P<0.01）。免疫小鼠外周血中T淋巴细胞的CD8+亚群增加了12%。
HSP70-PC通过激活细胞毒性T淋巴细胞（CTL）诱导抗肿瘤免疫，且具有强大的肿瘤疫苗效应。我们的研究为支持HSP70-PC用于对抗人类癌症的临床应用增添了更多证据。
